SCHEMBL16459658

SCHEMBL16459658

CC1(CO)COC(c2cccs2)=N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.38
MAPT P10636 3/20 0.38
DPP4 P27487 1/20 0.36
LPL P06858 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
ALOX5 P09917 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
KDM4E B2RXH2 6/20 0.34
ALDH1A1 P00352 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
RPS6KB2 Q9UBS0 2/20 0.33
GAA P10253 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GLA P06280 1/20 0.33
ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3890295 0.80 KDM4E (0.53) HPGDLMNAMAPTLPLLIPG
SCHEMBL12471989 0.75 LMNA (0.66) LMNAMAPTKDM4EALDH1A1
SCHEMBL16459165 0.73 LMNA (0.62) LMNAMAPTLPLLIPGHTR2B
SCHEMBL16475554 0.72 LMNA (0.39) HPGDLMNAMAPTLPLLIPG
SCHEMBL16459758 0.71 LMNA (0.47) LMNAMAPTKDM4EALDH1A1KMT2A
SCHEMBL16458474 0.71 LMNA (0.41) LMNAKDM4EALDH1A1
SCHEMBL16459876 0.71 LMNA (0.38) LMNAKDM4EALDH1A1
SCHEMBL23480876 0.70 LMNA (0.46) LMNAMAPTKDM4EALDH1A1NPC1
SCHEMBL16460055 0.70 LMNA (0.46) LMNAMAPTKDM4E
SCHEMBL16459397 0.70 LMNA (0.46) LMNAMAPTKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969585-B2 Method for producing optically active compound or salt thereof NAGASAKI UNIVERSITY (JP) 2015-03-03 US disclosed
US-8969585-B2 Method for producing optically active compound or salt thereof NAGASAKI UNIVERSITY (JP) 2015-03-03 US disclosed
US-8969585-B2 Method for producing optically active compound or salt thereof NAGASAKI UNIVERSITY (JP) 2015-03-03 US disclosed
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF NAGASAKI UNIVERSITY (JP) 2014-01-09 US disclosed
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF NAGASAKI UNIVERSITY (JP) 2014-01-09 US disclosed
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF NAGASAKI UNIVERSITY (JP) 2014-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF MINK1, MELK, MRPL21 HPGD 4625/4885LMNA 1949/4885MAPT 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.